LIWANLI Innovation Co., Ltd.

Taiwan Stock Exchange 3054.TW

LIWANLI Innovation Co., Ltd. Price to Sales Ratio (P/S) on January 14, 2025: 39.53

LIWANLI Innovation Co., Ltd. Price to Sales Ratio (P/S) is 39.53 on January 14, 2025, a -10.74% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

LIWANLI Innovation Co., Ltd. 52-week high Price to Sales Ratio (P/S) is 50.11 on December 31, 2024, which is 26.77% above the current Price to Sales Ratio (P/S).
LIWANLI Innovation Co., Ltd. 52-week low Price to Sales Ratio (P/S) is 39.14 on August 05, 2024, which is -0.98% below the current Price to Sales Ratio (P/S).
LIWANLI Innovation Co., Ltd. average Price to Sales Ratio (P/S) for the last 52 weeks is 43.11.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Taiwan Stock Exchange: 3054.TW

LIWANLI Innovation Co., Ltd.

CEO	Li Ching Chen
IPO Date	Nov. 19, 2002
Location	Taiwan
Headquarters	No. 258, Liancheng Road
Employees	360
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

LIWANLI Innovation Co., Ltd. operates in the biomedical science industry. It provides products in the areas of nutrition and healthcare. The company offers Vigoway and powder collection products for male, female, elderly, and children audience. Its products include probiotic enzymes, pro-active nutrients, resveratrol red grape extract, algae DHA soft gels, shea butter with type II collagen soft gels, algae astaxanthin Q10 soft gels, cordyceps militaries powder, tooth guard tablets, bovine and goat's milk bites, bilberry-tablets, DHA and vitamin D3 drops, and other products. The company was formerly known as Carry Technology International Co., Ltd. and changed its name to LIWANLI Innovation Co., Ltd. in 2015. LIWANLI Innovation Co., Ltd. was founded in 1980 and is based in New Taipei City, Taiwan.

Key trends

Past 5 years